GEN Exclusives

More »

GEN News Highlights

More »
Dec 18, 2007

Ambrx Allies with Merck & Co. in Type 2 Diabetes Drug Discovery Collaboration

  • Ambrx and Merck & Co. are collaborating on the development of a therapeutic protein with properties similar to Fibroblast Growth Factor 21 (FGF-21) for the treatment of type 2 diabetes and related metabolic disorders.

    Both parties will utilize Ambrx' protein technology, ReCODE™, to develop a chemically modified and optimized drug candidate designed to have improved therapeutic properties over the native FGF-21 protein.

    The collaboration includes an upfront and R&D payments from Merck. Additionally, Ambrx will be eligible to receive future milestone fees associated with research, development, and commercialization of a drug candidate along with royalties on net sales. The firm also has the right to exercise an end of Phase II profit sharing option.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »